

014811-673.119US

9/5/08

PTO/SB/026 (09-05)

Approved for use through 06/30/2006. GNS 0051-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/594,046	
			Filing Date	September 25, 2006	
			First Named Inventor	Nnochiri N. Ekwuribe	
			Art Unit	1614	
			Examiner Name	Phyllis G. Spivack	
Sheet	10	of	10	Attorney Docket Number	014811-673.119

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	341	M.C. DI PAOLO et al.: Sulisamitrazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. <i>Digest Liver Dis.</i> 2001; pp. 593-597; 33	duplicate duplicate duplicate
	242	E. K. FIELDS et al.: Diaryl Substituted Maleic Anhydrides; <i>J. Org. Chem.</i> 1993; pp. 5105-5170; 58; American Chemical Society	
	243	FRIEDRICH NERDEL et al.; <i>Chemical Abstracts</i> 1967; pp. 443-444; Vol. 65	
fs	244	Beilstein Search Results, 5522653, 1884.	duplicate
	245	FRANK D. KING, <i>Bioisosteres, Customized Molecular Simulation, and Pro-drugs - Case History: An Example of a Conformational Restriction Approach</i> (Medicinal Chemistry: Principles and Practice) 1994; pp. 206-225 (pp. 216-217, Table 4); Cambridge, 1997, 65	

Examiner Signature	<i>P. Spivack</i>	Date Considered	9/6/08
--------------------	-------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is in its (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.94. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.